IFNA2 and COVID-19: The frequency of CD8Ts was even lower, and the frequency of cMs was even higher in critical COVID-19+ cases with detectable anti–IFN-α2 antibodies than those without (CD8T: −5.8%, P < 10−5; cMs: +8.3%, P = 0.034) (Fig. 2C and data file S6).